🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Fostering Data Sharing

Search Papers Authors Institutions Grants FAIR About

TheSindex

Fostering Data Sharing

Empowering the data sharing that empowers science — an open, citation-grounded index for datasets.

Product

Search
API
Explore
Rankings

Resources

Methodology
Data Sources
Documentation
Press

Organization

About
Team
Wikidata

© 2026 theSindex. All rights reserved.

Home
Authors
Danlei Yu

Danlei Yu

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “The novel MET inhibitor, HQP8361, possesses single agent activity and enhances therapeutic efficacy of osimertinib, against NSCLC cells with acquired resistance to osimertinib due to MET amplification”.

The novel MET inhibitor, HQP8361, possesses single agent activity and enhances therapeutic efficacy of osimertinib, against NSCLC cells with acquired resistance to osimertinib due to MET amplification

Research Square (Research Square)(2020)10.21203/rs.3.rs-25317/v1

N/A

0DataRank · unranked

1 citations

Yiting Li, Kevin D.-Y. Sun, Jiajia Gu, Zhen Chen, Taofeek K Omonikoko +3 more

Nanoparticles for co-delivery of osimertinib and selumetinib to overcome osimertinib-acquired resistance in non-small cell lung cancer

Acta Biomaterialia(2021)10.1016/j.actbio.2021.05.018

N/A

0DataRank · unranked

51 citations

Danlei Yu, Shi‐Yong Sun, Feng Li, Chen Wu

Managing Acquired Resistance to Third-Generation EGFR Tyrosine Kinase Inhibitors Through Co-Targeting MEK/ERK Signaling

Lung Cancer Targets and Therapy(2021)10.2147/lctt.s293902

N/A

0DataRank · unranked

23 citations

Wen Zhao, Karin A. Vallega, Shi‐Yong Sun, Danlei Yu